Daniel Mulkerin

2.6k total citations
79 papers, 1.2k citations indexed

About

Daniel Mulkerin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Daniel Mulkerin has authored 79 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 13 papers in Pathology and Forensic Medicine. Recurrent topics in Daniel Mulkerin's work include Colorectal Cancer Treatments and Studies (27 papers), Cancer Treatment and Pharmacology (21 papers) and Pancreatic and Hepatic Oncology Research (8 papers). Daniel Mulkerin is often cited by papers focused on Colorectal Cancer Treatments and Studies (27 papers), Cancer Treatment and Pharmacology (21 papers) and Pancreatic and Hepatic Oncology Research (8 papers). Daniel Mulkerin collaborates with scholars based in United States, Germany and Canada. Daniel Mulkerin's co-authors include Noelle K. LoConte, Sam Joseph Lubner, Chris H. Takimoto, Kyle D. Holen, Scot C. Remick, Ramesh K. Ramanathan, Merrill J. Egorin, S. Percy Ivy, Sridhar Mani and Anne Hamilton and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Daniel Mulkerin

74 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Mulkerin United States	18	670	366	229	209	155	79	1.2k
Virginia E. Kwitkowski United States	16	423 0.6×	484 1.3×	264 1.2×	119 0.6×	192 1.2×	18	1.2k
Carsten Grüllich Germany	25	493 0.7×	557 1.5×	479 2.1×	258 1.2×	89 0.6×	90	1.5k
Melanie Poulin-Costello Canada	14	426 0.6×	491 1.3×	133 0.6×	137 0.7×	160 1.0×	36	1.1k
Sander Bins Netherlands	17	688 1.0×	376 1.0×	324 1.4×	86 0.4×	65 0.4×	59	1.2k
Véronique D’Hondt France	21	781 1.2×	298 0.8×	335 1.5×	163 0.8×	102 0.7×	83	1.3k
Lissandra Dal Lago Belgium	18	1.2k 1.7×	305 0.8×	254 1.1×	115 0.6×	108 0.7×	54	1.7k
Lucille Leong United States	23	691 1.0×	502 1.4×	265 1.2×	75 0.4×	162 1.0×	74	1.6k
Gennaro Gadaleta‐Caldarola Italy	19	406 0.6×	312 0.9×	261 1.1×	118 0.6×	129 0.8×	51	1.0k
Joanne Halsey United States	19	1.1k 1.7×	667 1.8×	298 1.3×	93 0.4×	149 1.0×	32	1.7k
Edgardo S. Santos United States	21	576 0.9×	384 1.0×	524 2.3×	69 0.3×	159 1.0×	101	1.2k

Countries citing papers authored by Daniel Mulkerin

Since Specialization

Citations

This map shows the geographic impact of Daniel Mulkerin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Mulkerin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Mulkerin more than expected).

Fields of papers citing papers by Daniel Mulkerin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Mulkerin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Mulkerin. The network helps show where Daniel Mulkerin may publish in the future.

Co-authorship network of co-authors of Daniel Mulkerin

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Mulkerin. A scholar is included among the top collaborators of Daniel Mulkerin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Mulkerin. Daniel Mulkerin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Krause, Diana N., Anne Gross, Daniel Mulkerin, et al.. (2022). Measuring Advanced Practice Provider Productivity at the National Comprehensive Cancer Network’s Member Institutions. Journal of the Advanced Practitioner in Oncology. 13(5). 507–513. 2 indexed citations

Ziemlewicz, Timothy J., Sam Joseph Lubner, Sharon M. Weber, et al.. (2021). Microwave ablation for colorectal cancer metastasis to the liver: a single-center retrospective analysis. Journal of Gastrointestinal Oncology. 12(4). 1454–1469. 17 indexed citations

Witt, Jacob S., Meghan G. Lubner, Scott B. Reeder, et al.. (2020). A Phase 1 Dose Escalation Study of Neoadjuvant SBRT Plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic Cancer. International Journal of Radiation Oncology*Biology*Physics. 109(2). 458–463. 8 indexed citations

Kratz, Jeremy D., Nataliya V. Uboha, Sam Joseph Lubner, et al.. (2018). Metastatic Bulk Independently Predicts Outcomes for EGFR Precision Targeting in Colorectal Cancer. Journal of the National Comprehensive Cancer Network. 16(12). 1442–1450. 5 indexed citations

Lubner, Sam Joseph, et al.. (2015). A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer. Cancer Chemotherapy and Pharmacology. 76(2). 317–323. 7 indexed citations

Deming, Dustin A., Ludimila Cavalcante, Sam Joseph Lubner, et al.. (2015). A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. Investigational New Drugs. 34(2). 168–175. 44 indexed citations

LoConte, Noelle K., Albiruni R. Abdul Razak, Percy Ivy, et al.. (2014). A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Investigational New Drugs. 33(1). 169–176. 33 indexed citations

LoConte, Noelle K., Kyle D. Holen, William R. Schelman, et al.. (2012). A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Investigational New Drugs. 31(4). 943–948. 9 indexed citations

Holen, Kyle D., Renata Jaskula‐Sztul, Daniel Mulkerin, et al.. (2011). A Pilot Phase II Study of Valproic Acid for Treatment of Low-Grade Neuroendocrine Carcinoma. The Oncologist. 16(6). 835–843. 72 indexed citations

10.

Galsky, Matthew D., Luis H. Camacho, E. Gabriela Chiorean, et al.. (2011). Retrospective Analysis of Satraplatin in Patients with Metastatic Urothelial Cancer Refractory to Standard Platinum-Based Chemotherapy. Clinical Genitourinary Cancer. 9(1). 27–30. 4 indexed citations

11.

Remick, Scot C., Chris H. Takimoto, Ramesh K. Ramanathan, et al.. (2011). Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. Cancer Chemotherapy and Pharmacology. 68(6). 1439–1447. 35 indexed citations

12.

Lubner, Sam Joseph, Noelle K. LoConte, Kyle D. Holen, et al.. (2010). A Phase II Study of Oxaliplatin, 5-Fluorouracil, Leucovorin, and High-Dose Capecitabine in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer. 9(3). 157–161. 6 indexed citations

13.

Tevaarwerk, Amyé, Richard R. Love, James A. Stewart, et al.. (2010). Randomized Trial of Adjuvant Zoledronic Acid in Postmenopausal Women With High-Risk Breast Cancer. Clinical Breast Cancer. 10(6). 471–476. 17 indexed citations

14.

Chan, Emily, Daniel Mulkerin, Mace L. Rothenberg, et al.. (2008). A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. Investigational New Drugs. 26(3). 241–247. 28 indexed citations

15.

Attia, Steven, Kyle D. Holen, Howard H. Bailey, et al.. (2008). Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies. Cancer Chemotherapy and Pharmacology. 64(1). 45–51. 4 indexed citations

16.

Bailey, Howard H., Dona Alberti, James P. Thomas, et al.. (2007). Phase I Trial of Weekly Paclitaxel and BMS-214662 in Patients with Advanced Solid Tumors. Clinical Cancer Research. 13(12). 3623–3629. 14 indexed citations

17.

Stewart, James A., et al.. (2003). Capecitabine-Related Neurotoxicity Presenting as Trismus. Clinical Colorectal Cancer. 3(2). 121–123. 26 indexed citations

18.

Thomas, James P., Daniel Mulkerin, Jordan Berlin, et al.. (2002). Phase I Study of Eniluracil, Oral 5-Fluororacil and Gemcitabine in Patients with Advanced Malignancy. Investigational New Drugs. 20(4). 377–382. 2 indexed citations

19.

Mulkerin, Daniel, et al.. (2002). Phase II Trial of Perillyl Alcohol in Patients with Metastatic Colorectal Cancer. International Journal of Gastrointestinal Cancer. 32(2-3). 125–128. 47 indexed citations

20.

Mentzel, M., et al.. (1997). Influence of circadian rhythm on 41.8°C whole body hyperthermia induction of haematopoietic growth factors. International Journal of Hyperthermia. 13(6). 571–576. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact